Published Manuscripts
“Significant Anti-tumor Effect of Bevacizumab in Treatment of Pineal Gland Glioblastoma Multiforme”
Targeted Oncology. 2014 Dec;9(4):395-8. doi: 10.1007/s11523-014-0327-8. Epub 2014 Jul 8
“Tumor Lysis Syndrome in Retroperitoneal Sarcoma”
Journal of Investigative Medicine High Impact Case Reports.. 2014 Jul-Sep; 2(3): 2324709614542340. Published online 2014 Jul 4. doi: 10.1177/2324709614542340
“ Congestive Heart Failure during induction with Anthracycline based therapy in patients with Acute Promyelocytic Leukemia may be more frequent than expected”
J Community Support Oncol. 2014 Nov;12(11):390-3. doi: 10.12788/jcso.0084
"Prognostic Value of Day 30 Platelet Count After First Induction Cycle in Acute Myeloid Leukemia."
Journal of Community and Supportive Oncology. October 2015.
“Utility and impact of early t(15;17) identification by Fluorescence In-Situ Hybridization (FISH) in clinical decision making for patients in Acute Promyelocytic Leukemia (APL)”
Int J Lab Hematol. 2015 Aug; 37(4):515-20. doi: 10.1111/ijlh.12326. Epub 2015 Jan 14.
"Pneumatosis Intestinalis in an Acute Promyelocytic Leukemia (APL) patient”
Case Reports in Hematology. October 2015. 2015;2015:576042. doi: 10.1155/2015/576042. Epub 2015 Oct 8
“Prognostic value of complete remission with superior platelet counts in Acute Myeloid Leukemia"
Journal of Community and Supportive Oncology. 2016 Feb;14(2):66-71. doi: 10.12788/jcso.0231
“Recurrent Metastatic Parotid Carcinosarcoma in an Asymptomatic Patient”
Journal of Investigative Medicine High Impact Case Reports. 2016 Nov 4;4(4):2324709616676590
“Rare Case of Spontaneous Tumor Lysis Syndrome (TLS) in a patient with Germ Cell Tumor (GCT): Literature Review and Approach to Management”
MOJ Clinical Med Case Rep. July 2017. DOI: 10.15406/mojcr.2017.07.00190
"Increased bone remodeling on patients treated with a CTLA-4 inhibitor: First report of an unknown autoimmune reaction"
Journal of Community and Supportive Oncology. August 2017. . doi: https://doi.org/10.12788/jcso.0340
“Outcomes of Patients with Multiple Myeloma Refractory to CD38 Targeted Monoclonal Antibody Therapy”
Leukemia. 2019 Mar 11. doi: 10.1038/s41375-019-0435-7
Published Abstracts
“Serum Alkaline Phosphatase Level on Day 4 of G-CSF Administration Could Be a Simple Yet Practical Surrogate Marker for CD34 Mobilization and Collection.”
Abstract # 65543 Publication # 4519. Blood. November, 2013
“Utility of D-Dimer As a Marker for Diffrentiation Syndrome and Infections in Acute Promyelocytic Leukemia (APL)”
Abstract # 65814 Publication # 4986. Blood. November, 2013
“Day 30 Platelet Count as a Prognostic Marker of Survival in Acute Myeloid Leukemia.”
Blood 124 (21). December, 2014
“Increased bone remodeling on patients treated with a CTLA-4 inhibitor: First report of an unknown autoimmune reaction.”
J Clin Oncol 33. June, 2015 (suppl; abstr e14027)
“Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Treatment.”
Blood 2018 132:2015; doi: https://doi.org/10.1182/blood-2018-99-115078
“Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment.”
Blood 2018 132:3233; doi: https://doi.org/10.1182/blood-2018-99-111033
“Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies.”
Blood 2018 132:3303; doi: https://doi.org/10.1182/blood-2018-99-112246